Arg972 insulin receptor substrate-1 inhibits endothelial nitric oxide synthase expression in human endothelial cells by upregulating microRNA-155

International Journal of Molecular Medicine

Volumn 36, Issue 1, 2015, Pages 239-248

  Huang, Cheng ^a   Li, Guang ^a   Dong, Haojian ^a   Sun, Shuo ^a   Chen, Haimin ^a   Luo, Demou ^a   Sun, Ling ^a   Li, Xida ^a   Chen, Zhujun ^a   Yang, Huijian ^a   Wei, Shuisheng ^a   Zhou, Yingling ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Endothelial cell; Endothelial nitric oxide synthase; Insulin receptor substrate 1; miR 155; Phosphatidylinositol 3 kinase

Indexed keywords

ARGININE 972 INSULIN RECEPTOR SUBSTRATE 1; ARGININE DERIVATIVE; BUPARLISIB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; MICRORNA; MICRORNA 125A; MICRORNA 125B; MICRORNA 126; MICRORNA 155; MICRORNA 218; MICRORNA 221; MICRORNA 222; NITRATE; NITRITE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; INSULIN RECEPTOR SUBSTRATE; MIRN155 MICRORNA, HUMAN; MORPHOLINE DERIVATIVE; NITRIC OXIDE; NVP-BKM120;

ADULT; AGED; ARTICLE; BLOOD VESSEL TONE; BODY MASS; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE FREQUENCY; GENETIC TRANSFECTION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; STABLE TRANSFECTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; DIABETES MELLITUS; GENETICS; INSULIN RESISTANCE; METABOLISM; PHOSPHORYLATION;

ADULT; AGED; AMINOPYRIDINES; CELLS, CULTURED; DIABETES MELLITUS; ENZYME ACTIVATION; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MICRORNAS; MIDDLE AGED; MORPHOLINES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; TRANSFECTION;

EID: 84930359182     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2192     Document Type: Article

References (31)

1. Schulz R, Rassaf T, Massion PB, Kelm M and Balligand JL: Recent advances in the understanding of the role of nitric oxide in cardiovascular homeo stasis. Pharmacol Ther 108: 225-256, 2005.
2. Balligand JL, Feron O and Dessy C: eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovas cular tissues. Physiol Rev 89: 481-534, 2009.
3. Förstermann U and Münzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708-1714, 2006.
4. Searles CD: Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J Physiol Cell Physiol 291: C803-C816, 2006.
5. Alonso J, Sánchez de Miguel L, Montón M, Casado S and López-Farré A: Endothelial cytosolic proteins bind to the 3′ untranslated region of endo thelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol Cell Biol 17: 5719-5726, 1997.
6. Lai PF, Mohamed F, Monge JC and Stewart DJ: Downregulation of eNOS mRNA expression by TNFalpha: identification and functional characterization of RNA-protein interactions in the 3′ UTR. Cardiovasc Res 59: 160-168, 2003.
7. Laufs U and Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
8. Yan G, You B, Chen SP, Liao JK and Sun J: Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res 103: 591-597, 2008.
9. Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet Med 15: 539-553, 1998.
10. Huang PL: eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 20: 295-302, 2009.
11. Huang PL: A comprehensive definition for metabolic syndrome. Dis Models Mech 2: 231-237, 2009.
12. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, et al: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22, 2001.
13. Steinberg HO, Brechtel G, Johnson A, Fineberg N and Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94: 1172-1179, 1994.
14. Scherrer U, Randin D, Vollenweider P, Vollenweider L and Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94: 2511-2515, 1994.
15. 1179. J Biol Chem 276: 30392-30398, 2001.
16. Zeng G, Nystrom FH, Ravichandran LV, Cong L, Kirby M, Mostowski H and Quon MJ: Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545, 2000.
17. Montagnani M and Quon MJ: Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. Diabetes Obes Metab 2: 285-292, 2000.
18. Fallucca F, Dalfrà MG, Sciullo E, Masin M, Buongiorno AM, Napoli A, Fedele D and Lapolla A: Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy. Metabolism 55: 1451-1456, 2006.
19. 972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 85: 2004-2013, 2000.
20. 972>Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest 104: 357-364, 1999.
21. 972 insulin receptor substrate-1 is associated with elevated plasma endothelin-1 level in hypertensives. J Hypertens 30: 1751-1757, 2012.
22. Federici M, Pandolfi A, De Filippis EA, Pellegrini G, Menghini R, Lauro D, Cardellini M, Romano M, Sesti G, Lauro R, et al: G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 109: 399-405, 2004.
23. 972 Insulin receptor substrate-1 is associated with decreased serum angiotensin-converting enzyme 2 levels in acute myocardial infarction patients: in vivo and in vitro evidence. Cardiovasc Diabetol 12: 151, 2013.
24. Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, et al: PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 115: 2128-2138, 2005.
25. Matsui T, Li L, del MonteF, Fukui Y, Franke TF, Hajjar RJ and Rosenzweig A: Adenoviral gene transfer of activated phosphatidylinositol 3′-kinaseand Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 373-2379, 1999.
26. Polit DF and Sherman RE: Statistical power in nursing research. Nurs Res 39: 365-369, 1990.
27. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, Zhang Q, Jiang Y, Huang LY, Tang YB, et al: Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 60: 1407-1414, 2012.
28. Chamorro-Jorganes A, Araldi E and Suarez Y: MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacol Res 75: 15-27, 2013.
29. Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, et al: SYK inhibition modulates distinct PI3K/Akt-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23: 826-838, 2013.
30. Lusis AJ: Atherosclerosis. Nature 407: 233-241, 2000.
31. Calles-Escandon J and Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22: 36-52, 2001.